Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 9, 2009 Dave Mock	A Big Upgrade for Gilead Sciences The biopharmaceutical company moves up to a five star rating from Motley Fool analysts.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
The Motley Fool March 1, 2010 Dave Mock	A Big Upgrade for Allstate After more than a year at a three-star rank, enough top-performing Motley Fool CAPS members have turned bullish on Allstate recently to upgrade it to a more formidable four stars.
The Motley Fool January 26, 2010 Dave Mock	A Big Upgrade for Cepheid Enough top-performing Motley Fool CAPS members have recently moved to the bull side of Cepheid to upgrade the molecular diagnostics firm from its four-star rank to a top-rated five stars.
The Motley Fool January 29, 2010 Dave Mock	A Big Upgrade for MetLife This bullish call comes from more than just one analyst.
The Motley Fool November 2, 2009 Dave Mock	A Big Upgrade for Hudson City Bancorp This bullish call comes from more than just one analyst.
The Motley Fool November 24, 2009 Dave Mock	A Big Upgrade for Time Warner After lumbering along at a lowly two-star rank for most of the past year, enough top-performing Motley Fool analysts have turned bullish on Time Warner recently to upgrade it to three stars.
The Motley Fool January 20, 2010 Dave Mock	A Big Upgrade for Smart Balance A total of 210 Motley Fool analysts have given their opinion on the food-products marketer, with many of them offering analysis and commentary explaining the recent optimism, and raising the stock to a four-star rating.
The Motley Fool November 11, 2009 Brian Orelli	Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis.
The Motley Fool January 13, 2010 Dave Mock	A Big Upgrade for The Buckle This bullish call comes from more than just one analyst.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
The Motley Fool February 23, 2010 Dave Mock	A Big Upgrade for Art Technology Group After being stuck for more than a year at no better than a three-star rank, enough top-performing CAPS members have turned bullish on e-commerce software provider Art Technology Group to upgrade it to a more formidable four stars.
The Motley Fool October 7, 2009 Dave Mock	A Big Upgrade for Tenet Healthcare This bullish call comes from more than just one analyst.
The Motley Fool March 8, 2010 Dave Mock	A Big Upgrade for National Semiconductor After being locked for more than six months at a less-than-impressive two-star rank, enough top-performing Motley Fool CAPS members have turned bullish on National Semiconductor recently to upgrade it to a more palatable three stars.
The Motley Fool January 27, 2010 Dave Mock	A Big Upgrade for Coinstar It had been stuck at a two-star rating for years, but enough top-performing Motley Fool CAPS members have turned bullish on Coinstar recently to upgrade it to a more formidable three stars.
The Motley Fool August 26, 2008 Dave Mock	A Big Upgrade for Southern This bullish call for electrical utility Southern comes from more than just one analyst.
The Motley Fool February 11, 2010 Brian Orelli	A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid.
The Motley Fool October 30, 2009 Brian Orelli	Shrugging Off the Side Effects Sanofi-aventis is looking good, but still faces the patent protection loss of Lovenox.
The Motley Fool September 11, 2008 Brian Lawler	Will a Change Cure Sanofi? The drugmaker charts a different course for its future.
The Motley Fool May 7, 2007 Brian Lawler	Sanofi Rolls the Lawsuit Dice Investors, don't be fooled by rosy results; litigation risk still looms for the French drugmaker.
The Motley Fool December 28, 2009 Dave Mock	A Big Upgrade for Gulf Resources Enough top-performing Motley Fool CAPS members have turned bullish on the chemicals maker recently to upgrade it to four stars.
The Motley Fool July 29, 2009 Brian Orelli	The Swine Flu Can't Save Sanofi No shocker there.
The Motley Fool July 23, 2009 Brian Orelli	The Slowly Wilting Lilly Nothing can save this drug company.
The Motley Fool February 14, 2008 Brian Lawler	Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops.
The Motley Fool December 16, 2008 Dave Mock	A Big Upgrade for AIG While it may be hard to believe, more top-performing CAPS members are turning bullish on American International Group these days, exhibiting optimism for the future.
The Motley Fool December 31, 2007 Brian Lawler	Big Pharma 2008 Forecast Roundup Investors, take a look at what 2008 has in store for big pharma.
The Motley Fool October 30, 2009 Brian Orelli	Of One-Time Gains and Pipelines AstraZeneca's earnings report illustrates the nature of polar opposites with one-time gains and new drugs. One is to be largely ignored, while the other will drive the drugmaker's future.
The Motley Fool November 1, 2006 Brian Lawler	Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note.
The Motley Fool November 23, 2009 Dave Mock	A Big Upgrade for Toyota Motor This bullish call comes from more than just one analyst.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
The Motley Fool October 31, 2007 Brian Lawler	Sanofi: Stable, for Now The drugmaker's healthy Q3 results shine amid slumping competitors. Investors, take note.
The Motley Fool August 30, 2010 Brian Orelli	Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition?
The Motley Fool April 30, 2010 Brian Orelli	Living the Blockbuster Model AstraZeneca's top drugs provide top-line growth in the first quarter.
The Motley Fool November 12, 2009 Dave Mock	A Big Upgrade for B&G Foods Enough Motley Fool analysts have become bullish on B&G Foods to elevate the stock to five-star status.
The Motley Fool December 12, 2008 Brian Orelli	A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors.
The Motley Fool August 31, 2005 Stephen D. Simpson	Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive.
The Motley Fool May 28, 2009 Brian Orelli	How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now?
The Motley Fool September 11, 2007 Brian Lawler	Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note.
The Motley Fool October 17, 2005 Brian Gorman	Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine.
The Motley Fool December 18, 2009 Brian Orelli	Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.
The Motley Fool November 30, 2009 Brian Orelli	Making Money More Efficiently Drug companies shape up, and it shows in their margins.
The Motley Fool May 5, 2006 Stephen D. Simpson	Sanofi-Aventis Waits It Out This is the hurry up-and-wait part of the French pharma's story, with product approvals on the way soon, investors hope.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool February 4, 2010 Brian Orelli	Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last?
The Motley Fool May 29, 2009 Brian Orelli	This Company Is Hot and Going Places Pharma company sanofi-aventis licenses a program, including two phase 1 compounds from Exelixis.
The Motley Fool September 16, 2009 Brian Orelli	Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration.
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool October 4, 2010 Brian Orelli	That's No Way to Make Friends Sanofi goes hostile on Genzyme.
The Motley Fool February 10, 2009 Robert Steyer	Rx for a Drug Deal? Will circumstance and psychology prod Sanofi-Aventis into a big acquisition?
The Motley Fool June 30, 2010 Rich Smith	This Just In: Upgrades and Downgrades Major Wall Street investment house Soleil Securities downgraded Eli Lilly shares to "sell."